Patents by Inventor Jie Xia

Jie Xia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170003757
    Abstract: An electronic device and a display processing method where the device includes a first body having a first surface and a second surface opposite to each other; a connecting body having a first surface and a second surface opposite to each other; a second body having a first surface and a second surface opposite to each other, which is connected to the first body through the connecting body. The electronic device has a first outer surface and a second outer surface; a first display arranged on at least a part of region on the first outer surface of the display having at least two modes of a second mode and a third mode; and a processor operative to control a third interface having at least a first sub interface and a second sub interface to be displayed on the third region in the third mode.
    Type: Application
    Filed: September 16, 2015
    Publication date: January 5, 2017
    Applicant: LENOVO (BEIJING) CO., LTD.
    Inventors: Ge Gao, Yan Gao, Jie Xia
  • Publication number: 20150160907
    Abstract: An information processing method is provided, which is applied to an electronic device. The electronic device includes a main body, a display unit and a projection unit. The method includes: obtaining trigger information for instructing the electronic device to switch from a first state to a second state; controlling the electronic device to switch from the first state to the second state in response to the trigger information; obtaining at least one parameter information; determining whether to enable the projection unit based on the at least one parameter information; and controlling the projection unit to be in the enabled state, in a case that it is determined to enable the projection unit based on the at least one parameter information.
    Type: Application
    Filed: September 24, 2014
    Publication date: June 11, 2015
    Inventors: Weiwei Zhang, Ge Gao, Jie Xia, Xu Zhao
  • Publication number: 20150160910
    Abstract: An information processing method and apparatus are provided in which a first switching operation instructs an electronic device to switch from a first mode to a second mode while the electronic device is in the first mode, in response to the first switching operation controlling the electronic device to switch from the first mode to the second mode, wherein a display unit set in a face of the electronic device acts as an auxiliary input unit and a projection unit, for projecting content, is set as an output unit while the electronic device is in the first mode; and wherein the display unit acts as an output unit and the projection unit is set as an auxiliary input unit while the electronic device is in the second mode.
    Type: Application
    Filed: August 21, 2014
    Publication date: June 11, 2015
    Inventors: Weiwei Zhang, Jie Xia
  • Patent number: 7893224
    Abstract: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: February 22, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jie Xia
  • Patent number: 7772387
    Abstract: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: August 10, 2010
    Assignee: Alnylam Pharmaceuticals
    Inventors: Muthiah Manoharan, Jie Xia, Kallanthottathil G. Rajeev
  • Publication number: 20090312531
    Abstract: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase.
    Type: Application
    Filed: July 31, 2009
    Publication date: December 17, 2009
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Jie XIA
  • Patent number: 7632932
    Abstract: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: December 15, 2009
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jie Xia
  • Publication number: 20090281298
    Abstract: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl.
    Type: Application
    Filed: July 1, 2009
    Publication date: November 12, 2009
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah MANOHARAN, Jie XIA, Kallanthottathil G. RAJEEV
  • Patent number: 7579451
    Abstract: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: August 25, 2009
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Jie Xia, Kallanthottathil G. Rajeev
  • Patent number: 7569686
    Abstract: The present invention provides compounds and methods of using them for preparing bicyclic nucleosides. The bicyclic nucleosides are useful for preparing chemically modified oligomeric compounds. Oligomeric compounds comprising these bicyclic nucleosides have enhanced properties such as increased nuclease resistance.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: August 4, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Jie Xia, Punit P. Seth, Guillermo Vasquez, Michael T. Migawa, Charles Allerson, Thazha P. Prakash, Eric E. Swayze
  • Publication number: 20070054279
    Abstract: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase.
    Type: Application
    Filed: August 4, 2005
    Publication date: March 8, 2007
    Applicant: Alnylam Pharmaceuticals
    Inventors: Muthiah Manoharan, Kallanthottathil Rajeev, Jie Xia
  • Publication number: 20060035254
    Abstract: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl.
    Type: Application
    Filed: July 21, 2005
    Publication date: February 16, 2006
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Jie Xia, Kallanthottathil Rajeev
  • Publication number: 20040229840
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Application
    Filed: October 28, 2003
    Publication date: November 18, 2004
    Inventors: Balkrishen Bhat, Anne B. Eldrup, Steven S. Carroll, David B. Olsen, Daniel R. McMasters, Malcolm MacCoss, Jie Xia
  • Patent number: 6451642
    Abstract: A method to implant NMOS polycrystalline silicon in embedded FLASH memory applications is described. In the method the polycrystalline silicon region (130) that will used to form the gate electrode of the NMOS transistor is doped simultaneously along with the source line in the FLASH memory array.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: September 17, 2002
    Assignee: Texas Instruments Incorporated
    Inventors: Freidoon Mehrad, Jie Xia, Thomas M. Ambrose
  • Patent number: 6429093
    Abstract: A method of forming a semiconductor component having a conductive line (24) and a silicide region (140) that crosses a trench (72). The method involves forming nitride sidewalls (127) to protect the stack during the silicidation process.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: August 6, 2002
    Assignee: Texas Instruments Incorporated
    Inventors: Jie Xia, Freidoon Mehrad, Mercer L. Brugler
  • Patent number: 6380031
    Abstract: A method to form an embedded FLASH integrated circuit with reduced processing steps is described. In the method a partial etch is performed on the control gate region of a polycrystalline silicon film (21). A multiple etch process is then used to simultaneously form the FLASH memory cell gate stack (54), the NMOS gate structure (94) and the PMOS gate structure (96).
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: April 30, 2002
    Assignee: Texas Instruments Incorporated
    Inventors: Freidoon Mehrad, Jie Xia, Sandra Zheng, Lancy Tsung